TrialBlood2020

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Giovanni Palladini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.